Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
0.9294
-0.0489 (-5.00%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Alector Revenue
In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth. Alector had revenue of $54.24M in the quarter ending December 31, 2024, with 257.08% growth.
Revenue (ttm)
$100.56M
Revenue Growth
+3.60%
P/S Ratio
0.88
Revenue / Employee
$422,513
Employees
238
Market Cap
91.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ALEC News
- 3 days ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire
- 22 days ago - Alector Provides Executive Leadership Update - GlobeNewsWire
- 7 weeks ago - Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Alector to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 2 months ago - Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call - GlobeNewsWire
- 3 months ago - Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 - GlobeNewsWire
- 4 months ago - Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts - Benzinga